BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/18/2021 1:32:04 PM | Browse: 328 | Download: 424
 |
Received |
|
2021-02-21 05:58 |
|
Peer-Review Started |
|
2021-02-21 06:02 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-05-10 00:25 |
|
Revised |
|
2021-05-17 14:01 |
|
Second Decision |
|
2021-07-26 03:25 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2021-07-26 06:50 |
|
Articles in Press |
|
2021-07-26 06:50 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-08-04 01:08 |
|
Typeset the Manuscript |
|
2021-09-17 17:15 |
|
Publish the Manuscript Online |
|
2021-09-18 13:32 |
| ISSN |
1948-9366 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Transplantation |
| Manuscript Type |
Minireviews |
| Article Title |
Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Yang Zhao, Yu Liu, Lin Zhou, Guo-Sheng Du and Qiang He |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Guo-Sheng Du, MD, Professor, Department of Faculty of Hepato-Pancreato-Biliary Surgery, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China. duguosheng309@126.com |
| Key Words |
Rapamycin; Hepatocellular carcinoma; Liver transplantation; Lenvatinib; Programmed death protein-1; Huaier granule |
| Core Tip |
Although liver transplantation (LT) is the radical method for patients with hepatocellular carcinoma (HCC) especially the advanced HCC by improving the survival benefits, the tumor recurrence post-operative seriously affects the survival of the graft and patients. The rapamycin (RAPA)-based immunosuppressive regimen has been recommended as a priority after LT due to its favorable survival benefits. In this presented study, we described the immune regulation and anti-tumor mechanism of RAPA, summarized the progress of RAPA transformation therapy after LT for HCC, further analyzed the survival benefits of combined anticancer drugs and targeted drugs, and combed the prospect of immune checkpoint therapy such as programmed cell death protein 1, in order to provide a theoretical basis for RAPA transformation therapy after LT for HCC. |
| Publish Date |
2021-09-18 13:32 |
| Citation |
Zhao Y, Liu Y, Zhou L, Du GS, He Q. Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma. World J Gastrointest Surg 2021; 13(9): 953-966 |
| URL |
https://www.wjgnet.com/1948-9366/full/v13/i9/953.htm |
| DOI |
https://dx.doi.org/10.4240/wjgs.v13.i9.953 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
